Prognostic value of baseline circulating tumor DNA (ctDNA) tumor fraction (TF) in metastatic hormone-sensitive prostate cancer (mHSPC)

被引：0
|
作者：
Nguyen, Charles B.
Tsung, Irene
Lee, Jessica K.
Pasquina, Lincoln W.
Kasputis, Amy
Lovett, Jennie L.
Graf, Ryon P.
Cackowski, Frank Cameron
Heath, Elisabeth I.
Morgan, Todd Matthew
Reichert, Zachery R.
机构：
[1] Univ Michigan, Rogel Comprehens Canc Ctr, Ann Arbor, MI 48109 USA
[2] Fdn Med Inc, Cambridge, MA USA
[3] Fdn Med Inc, San Diego, CA USA
[4] Wayne State Univ, Karmanos Canc Inst, Detroit, MI USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2024年 / 42卷 / 16期
基金：
美国国家卫生研究院;
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
5085
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Prognostic value of germline mutations in metastatic hormone-sensitive prostate cancer (mHSPC)
    Custodio-Cabello, Sara
    Pacheco-Barcia, Vilma
    Palka-Kotlowska, Magda
    Fernandez-Hernandez, Laura
    Del Alamo, Julio Fernandez
    Oliveros-Acebes, Eduardo
    Cabezon-Gutierrez, Luis
    UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS, 2024, 42 (10) : 331e13 - 331e24
  • [2] Genomic landscape of metastatic hormone sensitive prostate cancer (mHSPC) vs. metastatic castration refractory prostate cancer (mCRPC) by circulating tumor DNA (ctDNA).
    Hahn, Andrew W.
    Lin, Edwin
    Esther, John
    Anderson, Neysi
    Rathi, Nityam
    Yandell, Mark
    Maughan, Benjamin Louis
    Agarwal, Neeraj
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [3] Multigene Profiling of Circulating Tumor Cells (CTCs) for Prognostic Assessment in Treatment-Naive Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)
    Reichert, Zachery R.
    Kasputis, Tadas
    Nallandhighal, Srinivas
    Abusamra, Sophia M.
    Kasputis, Amy
    Haruray, Saloni
    Wang, Yugang
    Williams, Shamara
    Singhal, Udit
    Alva, Ajjai
    Cackowski, Frank C.
    Caram, Megan E. V.
    Palmbos, Phillip L.
    Yentz, Sarah E.
    Smith, David C.
    Alumkal, Joshi J.
    Morgan, Todd M.
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2022, 23 (01)
  • [4] Prognostic Significance of Circulating Tumor Cell Count in Patients With Metastatic Hormone-sensitive Prostate Cancer
    Resel Folkersma, Luis
    San Jose Manso, Luis
    Galante Romo, Isabel
    Moreno Sierra, Jesus
    Olivier Goemez, Carlos
    UROLOGY, 2012, 80 (06) : 1328 - 1332
  • [5] PROGNOSTIC SIGNIFICANCE OF THE QUANTIFICATION OF CIRCULATING TUMOR CELLS IN PATIENTS WITH METASTATIC HORMONE-SENSITIVE PROSTATE CANCER
    Resel, L.
    Olivier, C.
    San Jose, L.
    Galante, I
    Vidaurreta, M.
    Maestro, M.
    Diaz-Rubio, E.
    Silmi, A.
    EUROPEAN UROLOGY SUPPLEMENTS, 2011, 10 (02) : 142 - 143
  • [6] Prognostic value of circulating tumor DNA (ctDNA) in ovarian cancer
    Heo, J.
    Kim, Y-N.
    Lee, J-Y.
    Lee, S-T.
    Shin, S.
    Lee, K.
    Lee, Y. J.
    Kim, S. W.
    Choi, J. R.
    Kim, S.
    ANNALS OF ONCOLOGY, 2022, 33 (07) : S815 - S815
  • [7] Evaluating early changes in circulating tumor DNA (ctDNA) tumor fraction (TF) as a value add to PSA in predicting early progression in metastatic castrate resistant prostate cancer (mCRPC).
    Sweeney, Christopher
    Petry, Russell
    Xu, Chang
    Graf, Ryon
    Fabrizio, David
    He, Jie
    Gjoerup, Ole
    Pasquina, Lincoln
    Assaf, Zoe June
    Yuen, Kobe
    Wongchenko, Matthew J.
    Gupta, Pratyush
    Mariathasan, Sanjeev
    Powles, Thomas
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (4_SUPPL) : 196 - 196
  • [8] TITAN study: evaluation of apalutamide in patients with metastatic hormone-sensitive prostate cancer - Treatment of metastatic hormone-sensitive prostate cancer (mHSPC)
    Merseburger, Axel S.
    Suttmann, Henrik
    AKTUELLE UROLOGIE, 2021, 52 (02) : 155 - 160
  • [9] Article Circulating tumor DNA and tissue complementarily detect genomic alterations in metastatic hormone-sensitive prostate cancer
    Yang, Bin
    Zhao, Tingting
    Dong, Baijun
    Chen, Wei
    Yang, Guanjie
    Xie, Jun
    Guo, Changcheng
    Wang, Ruiliang
    Wang, Hong
    Huang, Longfei
    Peng, Bo
    Xue, Wei
    Yao, Xudong
    ISCIENCE, 2024, 27 (02)
  • [10] Use of abiraterone for patients with metastatic hormone-sensitive prostate cancer (mHSPC)
    Cathomas, R.
    ONCOLOGY RESEARCH AND TREATMENT, 2018, 41 : 130 - 130
12345